ResearcherShanghai Jiao Tong UniversityNo recent work listed
Hang Yin
Matched on ORCID iD 0000-0002-0260-9130; OpenAlex author ID A5030742167. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 1, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 7
2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper
Papers 5
- lncRNA ANRIL aggravates the chemoresistance of pancreatic cancer cells to gemcitabine by targeting inhibition of miR-181a and targeting HMGB1-induced autophagy. Last author DOI 10.18632/aging.203251↗
- ENO1-targeted superparamagnetic iron oxide nanoparticles for detecting pancreatic cancer by magnetic resonance imaging. First author DOI 10.1111/jcmm.15237↗
- ENO1 silencing impaires hypoxia-induced gemcitabine chemoresistance associated with redox modulation in pancreatic cancer cells. Co-author PMID 31396350↗
- ENO1 Overexpression in Pancreatic Cancer Patients and Its Clinical and Diagnostic Significance. Co-author DOI 10.1155/2018/3842198↗
- Analysis of Important Gene Ontology Terms and Biological Pathways Related to Pancreatic Cancer. Co-author DOI 10.1155/2016/7861274↗
Closest collaborators
The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Hailin Liu · 3 shared papers, 2016–2019 · strength 0.34
- Paper ENO1 Overexpression in Pancreatic Cancer Patients and Its Clinical and Diagnostic Significance. DOI 10.1155/2018/3842198↗
- Paper ENO1 silencing impaires hypoxia-induced gemcitabine chemoresistance associated with redox modulation in pancreatic canc… PMID 31396350↗
- Paper Analysis of Important Gene Ontology Terms and Biological Pathways Related to Pancreatic Cancer. DOI 10.1155/2016/7861274↗
- Lei Wang · 1 shared paper, 2021 · strength 0.17
- Lei Li · 1 shared paper, 2021 · strength 0.17
- H.-Y. Liu · 1 shared paper, 2020 · strength 0.13
- Lei Wang · 1 shared paper, 2020 · strength 0.13
- Lei Li · 1 shared paper, 2019 · strength 0.12
- Lei Wang · 1 shared paper, 2019 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.